Anti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)
Drug Alias NameTSHR CART targeted therapy - Innovative Cellular TherapeuticsTSHR CART cell - Innovative Cellular Therapeuticsanti-TSHR-CAR-T cell therapyAnti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy - Innovative Cellular TherapeuticsICTCAT-023
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionThyroid stimulating hormone receptor modulators
TargetsThyroid stimulating hormone receptor
Therapy Area/IndicationsThyroid Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsThyroid Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A